Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J. Ibrahim YH, et al. Among authors: ellisen lw. Cancer Discov. 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22. Cancer Discov. 2012. PMID: 22915752 Free PMC article.
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration.
Spring LM, Mortensen L, Abraham E, Keenan J, Medford A, Ma A, Padden S, Denault E, Ryan L, Iafrate AJ, Lennerz J, Hochberg E, Wander SA, Moy B, Isakoff SJ, Juric D, Brennan KA, Smith DE, Civiello B, Mulvey T, Comander A, Ellisen LW, Schwartz JH, Bardia A. Spring LM, et al. Among authors: ellisen lw. JCO Oncol Pract. 2024 Jan;20(1):69-76. doi: 10.1200/OP.23.00193. Epub 2023 Nov 3. JCO Oncol Pract. 2024. PMID: 37922440
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, Maheswaran S, Trippa L, Comander A, Mulvey T, McLaughlin S, Ryan P, Ryan L, Abraham E, Rosenstock A, Garrido-Castro AC, Lynce F, Moy B, Isakoff SJ, Tung N, Mittendorf EA, Ellisen LW, Bardia A. Spring LM, et al. Among authors: ellisen lw. Ann Oncol. 2024 Mar;35(3):293-301. doi: 10.1016/j.annonc.2023.11.018. Epub 2023 Dec 12. Ann Oncol. 2024. PMID: 38092228
Mechanisms of Resistance to Antibody-Drug Conjugates.
Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Abelman RO, et al. Among authors: ellisen lw. Cancers (Basel). 2023 Feb 17;15(4):1278. doi: 10.3390/cancers15041278. Cancers (Basel). 2023. PMID: 36831621 Free PMC article. Review.
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Medford AJ, Oshry L, Boyraz B, Kiedrowski L, Menshikova S, Butusova A, Dai CS, Gogakos T, Keenan JC, Occhiogrosso RH, Ryan P, Lennerz JK, Spring LM, Moy B, Ellisen LW, Bardia A. Medford AJ, et al. Among authors: ellisen lw. Ther Adv Med Oncol. 2023 Jan 30;15:17588359231152844. doi: 10.1177/17588359231152844. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36743521 Free PMC article.
130 results